Amebiasis, a disease caused by the protozoan Entamoeba histolytica, presents significant public health challenges, with approximately 50 million symptomatic cases reported globally.
Infection occurs primarily through the ingestion of cysts found in contaminated water or food sources, indicating a critical need for effective treatment options.
The application of engineered fungal molecules in drug discovery represents a promising avenue for developing new antiparasitic therapies, leveraging hybrid synthesis methods to enhance efficacy.